Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal... The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed. To predict potential side effects and novel medical uses, we generated comprehensive drug-protein interaction profiles by chemical proteomics for all 3 drugs. Our studies yielded 4 major findings: (1) The interaction profiles of the 3 drugs displayed strong differences and only a small overlap covering the ABL kinases. (2) Dasatinib bound in excess of 30 Tyr and Ser/Thr kinases, including major regulators of the immune system, suggesting that dasatinib might have a particular impact on immune function. (3) Despite the high specificity of nilotinib, the receptor tyrosine kinase DDR1 was identified and validated as an additional major target. (4) The oxidoreductase NQO2 was bound and inhibited by imatinib and nilotinib at physiologically relevant drug concentrations, representing the first nonkinase target of these drugs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Blood Pubmed

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Download PDF

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.


Abstract

The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed. To predict potential side effects and novel medical uses, we generated comprehensive drug-protein interaction profiles by chemical proteomics for all 3 drugs. Our studies yielded 4 major findings: (1) The interaction profiles of the 3 drugs displayed strong differences and only a small overlap covering the ABL kinases. (2) Dasatinib bound in excess of 30 Tyr and Ser/Thr kinases, including major regulators of the immune system, suggesting that dasatinib might have a particular impact on immune function. (3) Despite the high specificity of nilotinib, the receptor tyrosine kinase DDR1 was identified and validated as an additional major target. (4) The oxidoreductase NQO2 was bound and inhibited by imatinib and nilotinib at physiologically relevant drug concentrations, representing the first nonkinase target of these drugs.

Loading next page...
 
/lp/pubmed/chemical-proteomic-profiles-of-the-bcr-abl-inhibitors-imatinib-2km4Lx6DFx

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0006-4971
DOI
10.1182/blood-2007-07-102061
pmid
17720881

Abstract

The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed. To predict potential side effects and novel medical uses, we generated comprehensive drug-protein interaction profiles by chemical proteomics for all 3 drugs. Our studies yielded 4 major findings: (1) The interaction profiles of the 3 drugs displayed strong differences and only a small overlap covering the ABL kinases. (2) Dasatinib bound in excess of 30 Tyr and Ser/Thr kinases, including major regulators of the immune system, suggesting that dasatinib might have a particular impact on immune function. (3) Despite the high specificity of nilotinib, the receptor tyrosine kinase DDR1 was identified and validated as an additional major target. (4) The oxidoreductase NQO2 was bound and inhibited by imatinib and nilotinib at physiologically relevant drug concentrations, representing the first nonkinase target of these drugs.

Journal

Blood – Pubmed

Published: Dec 26, 2007

References

  • The biology of chronic myelogenous leukemia: implications for imatinib therapy.
    Alvarez
  • Chronic myeloid leukemia.
    Sawyers
  • Imatinib as a paradigm of targeted therapies.
    Druker
  • Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
    Nagar
  • Structural basis for the autoinhibition of c-Abl tyrosine kinase.
    Nagar
  • Circumventing resistance to kinase-inhibitor therapy.
    Druker
  • Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
    Shah
  • Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
    Weisberg
  • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
    Kantarjian
  • Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
    Lombardo
  • Overriding imatinib resistance with a novel ABL kinase inhibitor.
    Shah
  • A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy [abstract].
    Giles
  • Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI) [abstract].
    Jabbour
  • Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz
  • Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
    Carter
  • A small molecule-kinase interaction map for clinical kinase inhibitors.
    Fabian
  • Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.
    Knockaert
  • Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography.
    Guiffant
  • An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.
    Godl
  • Characterisation of kinase-selective inhibitors by chemical proteomics.
    Daub
  • Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry.
    Schirle
  • Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor.
    Jamieson
  • AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.
    Weisberg
  • The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
    Tokarski
  • A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain.
    Johnson
  • The Btk tyrosine kinase, is a major target of the anti-leukemic Bcr-Abl inhibitor dasatinib.
    Hantschel
  • Identification and characterization of a novel MAP kinase kinase kinase, MLTK.
    Gotoh
  • Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
    Ren
  • Regulating the regulator: negative regulation of Cbl ubiquitin ligases.
    Ryan
  • The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas.
    Paterson
  • Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
    Hu
  • ILK, PINCH and parvin: the tIPP of integrin signalling.
    Legate
  • Crystal structure of quinone reductase 2 in complex with resveratrol.
    Buryanovskyy
  • Crystal structure of human quinone reductase type 2, a metalloflavoprotein.
    Foster
  • Case histories, magic bullets and the state of drug discovery.
    Drews
  • Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology.
    van der Greef
  • Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
    Gambacorti-Passerini
  • NRH:quinone reductase 2: an enzyme of surprises and mysteries.
    Vella
  • Activation of discoidin domain receptor 1 isoform b with collagen up-regulates chemokine production in human macrophages: role of p38 mitogen-activated protein kinase and NF-kappa B.
    Matsuyama
  • Discoidin domain receptor 1: a new class of receptor regulating leukocyte-collagen interaction.
    Yoshimura
  • Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion and adhesion in association with matrix metalloproteinase-2.
    Ram
  • Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer.
    Heinzelmann-Schwarz
  • Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis.
    Matsuyama
  • Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium.
    Sakamoto
  • Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
    Maxwell
  • Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
    Lindvall
  • BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
    Donato